Navigation Links
Jazz Pharmaceuticals Announces Third Quarter 2011 Financial Results
Date:11/1/2011

PALO ALTO, Calif., Nov. 1, 2011 /PRNewswire/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced financial results for the third quarter of 2011.

Total revenues for the quarter ended September 30, 2011 were $73.3 million, compared to $44.8 million for the third quarter of 2010.  Total revenues include net product sales, royalties and contract revenues.

Adjusted net income for the third quarter of 2011 was $44.3 million, or $0.94 per diluted share, compared to $17.2 million, or $0.41 per diluted share, for the third quarter of 2010.  A reconciliation of GAAP net income to adjusted net income and the related per diluted share amounts is included with this press release.

GAAP net income for the third quarter of 2011 was $32.5 million, or $0.69 per diluted share, compared to a GAAP net income of $13.2 million, or $0.32 per diluted share, for the third quarter of 2010.  The company's GAAP net income in the third quarter of 2011 included costs of $6.0 million associated with the proposed transaction with Azur Pharma Public Limited Company (formerly Azur Pharma Limited) announced in September and a loss on extinguishment of debt of approximately $1.1 million associated with prepayment of a term loan in July 2011.

Net sales of Xyrem® (sodium oxybate) increased significantly to $62.5 million for the third quarter of 2011, compared to net sales of $37.2 million for the third quarter of 2010.  Net sales of once-daily Luvox CR® (fluvoxamine maleate) were $9.7 million for the third quarter of 2011, compared to $6.6 million for the prior year period.

"This strong quarter reflects the continued success of Xyrem as an important medical therapy for patients experiencing the two key symptoms of narcolepsy," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals.  "In the quarter, w
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Back-Up Compounds and S1P1 Lead Compounds, Assets Generated by Epix Pharmaceuticals, Inc. and Amgen, Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale
2. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results
3. Rock Creek Pharmaceuticals Announces Completion of Medical Conferences on Anatabloc™ Research, Comments on Research Presentation at American Thyroid Association Annual Meeting
4. Avanir Pharmaceuticals Submits European Marketing Authorization Application for NUEDEXTA
5. Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results
6. Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
7. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results on November 3, 2011
8. Endo Pharmaceuticals Reports Strong Third-Quarter Financial Results and Reaffirms 2011 Financial Guidance
9. Ground Zero Pharmaceuticals, Inc. (GZP) Announces Expansion of Oncology Programs for Its Clients
10. Thomas Dietz, Ph.D., Elected Chairman of Galleon Pharmaceuticals
11. Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - October 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 2, 2015 ... Society of Clinical Oncology    PharmaMar comunica ... SAR3007, resi noti dal dipartimento Ricerca e sviluppo ... miglioramento della sopravvivenza libera da progressione (PFS) dopo il ... con dacarbazina in pazienti con liposarcoma (LPS) o leiomiosarcoma ...
(Date:6/1/2015)... June 2, 2015 Amgen (NASDAQ: ... on a Phase 1b study to evaluate the ... oncolytic immunotherapy, in combination with Roche,s investigational anti-PDL1 ... with triple-negative breast cancer and colorectal cancer with ... investigational oncolytic immunotherapy designed to selectively replicate in ...
(Date:6/1/2015)... 1, 2015 Research ... the addition of the "Analysis of ... report to their offering.      ... in-depth analysis of the US Medical Image ... market dynamics, and trends across the US ...
Breaking Medicine Technology:PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 2PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 3PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 4PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 5PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 6Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 2Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 3Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 4Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 5Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 6Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 7Analysis of the US Medical Image Displays Market 2015-2017 2
(Date:6/2/2015)... 02, 2015 Mercy Health (formerly Catholic ... and Kentucky – has devoted the seventh of its ... skin cancer prevention. One in five Americans will get ... Health’s YouTube channel, a Mercy Health expert addresses these ... main causes of skin cancer? ,     What are ...
(Date:6/2/2015)... The Radiosurgery Society® (RSS), a ... RSSearch® Patient Registry evaluating the treatment patterns and ... the treatment of centrally located primary non-small cell ... The study, published in the May, 2015, issue ... patients with 114 centrally located lung tumors who ...
(Date:6/2/2015)... 02, 2015 FDA approved Orlistat for ... patients after a satisfactory doctor consultation. The less potent, over-the-counter ... several years and has the longest track record as an ... enzyme that breaks down fats in foods, Orlistat treatment prevents ... intestinal system to be excreted through feces. , ...
(Date:6/2/2015)... June 02, 2015 Thermi, formerly ... company has successfully transitioned into its new company ... to the company’s continued rapid worldwide expansion and ... of over 25 Thermi employees, including those of ... teams. , “As one of the fastest growing ...
(Date:6/2/2015)... 2015 While the movie box office ... books, comic books themselves are stepping into a new ... plans to produce educational comics in multiple languages that ... Sustainable Development - an international effort to address humanity’s ... education, sustainable energy, inequality, climate change and more. , ...
Breaking Medicine News(10 mins):Health News:Video provides helpful information about skin cancer prevention 2Health News:New Study from RSSearch® Patient Registry Highlights Treatment Patterns and Clinical Outcomes of Stereotactic Radiosurgery for Central Lung Tumors 2Health News:New Study from RSSearch® Patient Registry Highlights Treatment Patterns and Clinical Outcomes of Stereotactic Radiosurgery for Central Lung Tumors 3Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 2Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 3Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 4Health News:Thermi Moves to New Corporate Headquarters as Rapid Company Expansion Continues 2Health News:Can Comics Help the United Nations Save the World? 2Health News:Can Comics Help the United Nations Save the World? 3
... 2008: , The guidelines are developed through a ... in the field and a review committee of 21 ... for the first time both acute and chronic heart ... that patients with acute heart failure often develop chronic ...
... Lingering depression is a serious and common ... well with existing treatments. Because individuals with ... deficiency, an antioxidant that protects cells from toxins, ... in the September 15th issue of Biological ...
... study to date examining the impact of positron emission ... suspected recurrent colorectal cancer, researchers found that treatment plans ... to an article in the September issue of ... was conducted at four sites throughout Australia and comprised ...
... and Drug Administration Modernization Act (FDAMA, 1997), designed to ... in more than 130 label changes since its inception ... Children,s Hospital. , Their analysis appears in the September ... subsequent renewal of this legislation, pharmaceutical companies were given ...
... CHICAGO, Sept. 1 Dr. Charmaine Yoest,President and CEO ... response to news that the daughter of McCain running ... five children, I know this situation is not the ... we react to life,s,challenges is the true testament to ...
... and have higher heart rates, researchers say , , MONDAY, ... games, and playing active versions of these games may ... Kong researchers report. , In fact, children playing ... four times as many calories a minute than children ...
Cached Medicine News:Health News:New study finds that add-on therapy improves depressive symptoms in bipolar disorder 2Health News:PET scans lead to treatment changes in majority of colorectal cancer patients 2Health News:Post-marketing studies finding adverse events in drugs used in children 2Health News:Post-marketing studies finding adverse events in drugs used in children 3Health News:Active Video Games Help Kids Exercise 2Health News:Active Video Games Help Kids Exercise 3
... is a plastic device that fits over a ... with a minimum amount of reagent. , ... gap between the coverplate and slide. The ... reagent is dispensed into the well. Its ...
The first instrumentation to automate and efficiently manage the slide labeling process. Proven technology automatically feeds, prints and collates slides sequentially. Extensive data customization, ...
... wall-mounted organizer with a complete set of micro ... The Micro Nest makes it easier for technicians ... task. These small instrument cleaning brushes from ISI ... as cannulas. ISI Micro Brushes are available in ...
... "SSK" stands for Stainless Steel ... convenient instrument rust and stain remover for ... extend the life of your instruments by ... deposits. The result: pivot points, box joints ...
Medicine Products: